Inventiva S.A. is a biopharmaceutical company that focuses on developing oral therapies for NASH, MPS, and other diseases. Its main product candidate, Lanifibranor, has completed Phase IIb trial for NASH treatment, while Odiparcil has completed Phase IIa trial for MPS VI subtype disease. The company also has strategic alliances with AbbVie and Boehringer Ingelheim to revolutionize treatments for autoimmune diseases and idiopathic pulmonary fibrosis.